Back to top

GILEAD SCIENCES ANNOUNCES AGREEMENT WITH TIBOTEC PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE NEW FIXED-DOSE COMBINATION OF TRUVADAŽAND TMC278 ? Product Would Represent Second Truvada-Based Complete Fixed-Dose Regimen

Development Agreement
GILEAD SCIENCES ANNOUNCES AGREEMENT WITH TIBOTEC PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE NEW FIXED-DOSE COMBINATION OF TRUVADAŽAND TMC278 ? Product Would Represent Second Truvada-Based Complete Fixed-Dose Regimen | Document Parties: GILEAD SCIENCES INC | Gilead Sciences, Inc | TIBOTEC PHARMACEUTICALS You are currently viewing:
This Development Agreement involves

GILEAD SCIENCES INC | Gilead Sciences, Inc | TIBOTEC PHARMACEUTICALS

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
Title: GILEAD SCIENCES ANNOUNCES AGREEMENT WITH TIBOTEC PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE NEW FIXED-DOSE COMBINATION OF TRUVADAŽAND TMC278 ? Product Would Represent Second Truvada-Based Complete Fixed-Dose Regimen
Date: 7/16/2009
Industry: Biotechnology and Drugs     Sector: Healthcare

GILEAD SCIENCES ANNOUNCES AGREEMENT WITH TIBOTEC PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE NEW FIXED-DOSE COMBINATION OF TRUVADAŽAND TMC278 ? Product Would Represent Second Truvada-Based Complete Fixed-Dose Regimen, Parties: gilead sciences inc , gilead sciences inc , tibotec pharmaceuticals
50 of the Top 250 law firms use our Products every day

 

SITE SEARCH

AGREEMENTS / CONTRACTS

Document Title:

Entire Document: (optional)

Governing Law:(optional)


Try our advanced search >>
 

CLAUSES

Search Contract Clauses >>

Browse Contract Clause Library>>

Get Email Updates
Email:
This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more